Navigation Links
Therapure Biopharma Inc. Awarded US Government Contract for Development of Anti-Nerve Gas Agent

Mississauga, ON (PRWEB) June 11, 2013

Therapure Biopharma Inc., a contract development and manufacturing organization (CDMO) of biotherapeutics, is pleased to announce the company will participate as a subcontractor for DynPort Vaccine Company LLC (DVC), a CSC company, that was awarded a US cost-plus-fixed-fee contract with a maximum value of $157.3 million (prime contract number W911QY-13-C-0056) by the US Department of Defense (DoD) to support the development of a prophylactic countermeasure to prevent the effects of organophosphorus nerve agent poisoning.

Therapure’s subcontract under the above prime contract includes process optimization as well as manufacture of all clinical and nonclinical materials (drug product) to support DVC’s contract to develop, test and obtain the US Food and Drug Administration (FDA) approval for human plasma-derived butyrylcholinesterase (HuBChE), a blood plasma protein that binds and inactivates nerve agents. Mr. Nick Green, Therapure’s President and Chief Executive Officer, said: “We are delighted to partner with DVC to develop and manufacture medical counter measures for the US Department of Defense as part of a defense strategy against a wide range of nerve gases. Therapure successfully completed a rigorous selection and approval process to serve as the manufacturing subcontractor under the prime contract, which is a testament to the Company’s standards and capabilities in biomanufacturing. It is an honor to be part of this very critical initiative to protect US Servicemen and women.”

Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the U.S. Department of Defense, Department of the Army, Chemical Biological Medical Systems Joint Project Management Office (CBMS JPMO), Medical Identification and Treatment Systems Joint Product Management Office (MITS JPMO).

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a CDMO, Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop innovative and efficient solutions to advance client products from discovery to market. Therapure’s 130,000 sq. ft. facility includes manufacturing, research and quality-control laboratories and is built to U.S. FDA, EMA, MHRA and Health Canada standards.

For more information, please visit:

Company Contact:
Dina Iezzi
Director, Marketing and Special Projects

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Monoclonal Antibodies Market Dealmaking in Biopharma Industry Analyzed in New Research Report at
2. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
3. $9 million grant awarded to UH to study, treat learning disabilities
4. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
5. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
6. Grant awarded to help improve problem-solving skills for deaf and hard-of-hearing students
7. Southeast program to fight diabetes awarded nearly $10 million by HHS
8. Clemson professor awarded nearly $600,000 4-year grant to study language of plants
9. 29 Johns Hopkins stem cell researchers awarded funding
10. Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains
11. FirstVitals Health and Wellness, Inc. awarded $4 Million CMS Innovation Grant for Unique Telehealth Diabetes Progam Focused on Glycemic Control and Prevention of Diabetic Foot Complications
Post Your Comments:
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... 12, 2017 , ... Planet Fitness, one of the largest and fastest growing ... open a flagship location in Covington, LA at 401 N. U.S. Highway 190, in ... to Office Depot in the Holiday Square shopping center. Its location allows it to ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... GRAND RAPIDS, Mich. (PRWEB) , ... October 12, ... ... OnSite Wellness, has been named one of Michigan’s 2017 Best and Brightest in ... Best and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: